| 增强紫杉醇对结直肠癌化疗疗效的研究进展 |
| 投稿时间：2020-07-08 修订日期：2020-09-10 点此下载全文 |
| 引用本文：陈炳辰,于恩达.增强紫杉醇对结直肠癌化疗疗效的研究进展[J].药学实践杂志,2020,38(6):501~505 |
| 摘要点击次数: 932 |
| 全文下载次数: 711 |
|
| 基金项目:国家自然科学基金（81802434，1870455）；长海医院234学科攀峰计划（2019YXK036） |
|
| 中文摘要:结直肠癌作为我国发病率逐年增高的一种恶性肿瘤，由于其隐匿的临床表现及有限的筛查手段，许多患者确诊时已发生较深的肿瘤浸润或出现了远处转移，此时则需要做术后化疗或新辅助化疗。而现有的结直肠癌化疗方案由于其不良反应多且易产生耐药性，故许多学者均在积极探索新的其他可用于结直肠癌的化疗药物。紫杉醇是治疗乳腺癌、卵巢癌、胰腺癌等恶性肿瘤的一线化疗药物，但结直肠癌细胞却易对其产生耐药性，治疗效果不理想，但可以通过开发新的给药系统、与其他药物联合用药等方式增强对结直肠癌的疗效。针对紫杉醇治疗结直肠癌的有效治疗策略进行综述，以期为结直肠癌更有效的化疗方案提供新的思路。 |
| 中文关键词:紫杉醇 结直肠癌 化疗 |
| |
| The research progress on the efficacy enhancement of paclitaxel in chemotherapy for colorectal cancer |
|
|
| Abstract:Colorectal cancer is a malignant tumor with increasing incidence in China. Chemotherapy or neoadjuvant therapy are needed when the patients have deep tumor invasion of distant metastasis due to the hidden clinical manifestations and limited screening methods for the colorectal cancer. With many side effects of the current chemo-medications and the drug resistance, researchers are actively exploring new chemotherapy drugs for colorectal cancer. Paclitaxel is a first-line chemotherapy drug for the treatment of breast cancer, ovarian cancer, pancreatic cancer and other malignant tumors. Colorectal cancer cells are prone to become resistant to paclitaxel and the treatment efficiency was limited. However, new drug delivery systems and the combination drug therapy can enhance the treatment efficiency. This article reviews the effective treatment strategies of paclitaxel for colorectal cancer with the hope for new ideas and more effective chemotherapy. |
| keywords:paclitaxel colorectal cancer chemotherapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
